The Wall Street Journal Subscription
Pfizer Inc. laid out a timetable for reaching key milestones in the development of its Covid-19 vaccine that could mean the shots start becoming available in the U.S. before year’s end.
Chief Executive Albert Bourla said Friday the company could start to see from a large study whether the vaccine works by the end of this month and would have data on its safety by the third week of November. If the preliminary results indicate the vaccine can work safely, Pfizer could ask U.S. health regulators to permit use by late November.
Read More →
By By Bojan Pancevski and Jared S. Hopkins | 16 Oct 2020
